Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 250

Sort by

Sort Order Select

Journal Articles

Molecular Characteristics Influencing Relapse Risk in Low-Risk Pediatric Acute Myeloid Leukemia

Lusha Cao, Yang Xu, Tina Glisovic-Aplenc, Han R Fisher, Saamia Farooki, Kelly D. Getz, Todd A. Alonzo, Alan S Gamis, Soheil Meshinchi, Yi Xing, Richard Aplenc

Blood (2024) 144 (Supplement 1): 2932.

https://doi.org/10.1182/blood-2024-200851

Published: 2024

Journal Articles

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Michele S. Redell, Robert Gerbing, Todd A. Alonzo, Jim Wang, Maureen O'Brien, Sarah K. Tasian, Matthew A. Kutny, Todd M Cooper

Blood (2024) 144 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2024-200978

Published: 2024

Journal Articles

Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia

Francisco Marchi, Ann-Kathrin Schade, Vivek M. Shastri, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Jeffery M Klco, Alan S Gamis, Rhonda E. Ries, Anders Kolb, Richard Aplenc, Todd A. Alonzo, Stanley Pounds, Soheil Meshinchi, Jatinder K. Lamba

Blood (2024) 144 (Supplement 1): 103.

https://doi.org/10.1182/blood-2024-207665

Published: 2024

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 967.

https://doi.org/10.1182/blood-2024-205666

Published: 2024

Journal Articles

Gene Expression Profiling in Pediatric AML Patients with Febrile Neutropenia during Induction Therapy

Satyavardhan Rao Nittu, Nam Nguyen, Jim Wang, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Anders Kolb, Soheil Meshinchi, Jatinder K. Lamba

Blood (2024) 144 (Supplement 1): 6119.

https://doi.org/10.1182/blood-2024-210446

Published: 2024

Journal Articles

DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML

Rhonda E Ries, Xiaotu Ma, Claudia Tregnago, Todd A. Alonzo, Jim Wang, Tiffany Hylkema, Benjamin J Huang, Alireza Torabi, Jack H Peplinski, Logan K Wallace, Richard Aplenc, Alan S Gamis, Katherine Tarlock, Franco Locatelli, Martina Pigazzi, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2023-181060

Published: 2023

Journal Articles

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Martina Pigazzi, Claudia Tregnago, Rhonda E Ries, Maddalena Benetton, Todd A. Alonzo, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils Von Neuhoff, Henrik Hasle, Dirk Reinhardt, Franco Locatelli, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 840.

https://doi.org/10.1182/blood-2023-181872

Published: 2023

Journal Articles

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Richard J Marrero, Vivek M. Shastri, Richard Aplenc, Todd Cooper, Todd A. Alonzo, Alan S Gamis, Jim Wang, Soheil Meshinchi, E. Anders Kolb, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2023-187515

Published: 2023

Journal Articles

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

Nastassja Scheidegger, Gabriela Alexe, Delan Khalid, Rhonda E Ries, Jim Wang, Todd A. Alonzo, Jennifer Perry, Scott A Armstrong, Soheil Meshinchi, Yana Pikman, Kimberly Stegmaier

Blood (2023) 142 (Supplement 1): 166.

https://doi.org/10.1182/blood-2023-185561

Published: 2023

Journal Articles

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Benjamin J Huang, Lauren K. Meyer, Adam Lamble, Jim Wang, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Katherine Tarlock, Todd Cooper, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Joseph Chewning, William G. Woods, John T. Horan

Blood (2023) 142 (Supplement 1): 655.

https://doi.org/10.1182/blood-2023-186955

Published: 2023

Journal Articles

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Satyavardhan Rao Nittu, Francisco Marchi, Nam Nguyen, Vivek M. Shastri, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Jeffery Klco, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2023-189029

Published: 2023

Journal Articles

Integrated Methylation and Transcriptional Landscape and Evolution of Pediatric AML

Benjamin J Huang, Hamid Bolouri, Colin Y. Smith, Jim Wang, Rhonda E Ries, Elizabeth Conran, Alan S Gamis, Richard Aplenc, Todd A. Alonzo, Xiaotu Ma, Timothy Junius Triche, Jason E Farrar, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2023-187819

Published: 2023

Journal Articles

Reclassification of ETS Family Transcription Factor Fusions in Pediatric AML Based on Molecular Drivers

Nathaniel J Buteyn, Connor Burke, Eve Gardner, Vincent J Sartori, Rhonda E Ries, Todd A. Alonzo, Soheil Meshinchi, Timothy Triche, Jr.

Blood (2023) 142 (Supplement 1): 4298.

https://doi.org/10.1182/blood-2023-189474

Published: 2023

Journal Articles

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Todd Cooper, E. Anders Kolb, Soheil Meshinchi, Stanley Pounds, Christopher Vulpe, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2023-178832

Published: 2023

Journal Articles

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 121.

https://doi.org/10.1182/blood-2023-186894

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Blood (2023) 142 (Supplement 1): 835.

https://doi.org/10.1182/blood-2023-186505

Published: 2023

Journal Articles

CREBBP alterations are associated with a poor prognosis in de novo AML

Adam J. Lamble, Kohei Hagiwara, Robert B. Gerbing, Jenny L. Smith, Pandurang Kolekar, Rhonda E. Ries, Edward A. Kolb, Todd A. Alonzo, Xiaotu Ma, Soheil Meshinchi

Blood (2023) 141 (17): 2156–2159.

https://doi.org/10.1182/blood.2022017545

Published: 2023

Includes: Supplemental data

Journal Articles

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood (2022) 140 (Supplement 1): 745–747.

https://doi.org/10.1182/blood-2022-162526

Published: 2022

NARROW

Molecular Characteristics Influencing Relapse Risk in Low-Risk Pediatric Acute Myeloid Leukemia

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Gene Expression Profiling in Pediatric AML Patients with Febrile Neutropenia during Induction Therapy

DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Integrated Methylation and Transcriptional Landscape and Evolution of Pediatric AML

Reclassification of ETS Family Transcription Factor Fusions in Pediatric AML Based on Molecular Drivers

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

CREBBP alterations are associated with a poor prognosis in de novo AML

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only